Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SHR-1703 in eosinophilic asthma
CTR20243963Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1703 in eosinophilic asthma (EA), sponsored by Hengrui Therapeutics. Started Dec 2024; status: active.
02
Drugs
SHR-1703
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on CTR20243963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243963.